Alpha Tau Medical Sets Up 2026 for Critical Cancer Therapy Milestones — Alpha Tau Medical Ltd.

Event summary

Alpha Tau Medical is running five concurrent U.S. trials for Alpha DaRT, targeting skin, pancreatic, brain, and prostate cancers.
Patient recruitment for the pancreatic cancer trial (IMPACT) is set to complete by Q1 2026, with initial results expected by year-end.
The company anticipates a regulatory decision from Japan’s Ministry of Health, Labour and Welfare for Alpha DaRT in recurrent head & neck cancer.
Alpha Tau is preparing for a potential sixth U.S. trial combining Alpha DaRT with checkpoint inhibitors for head & neck cancer.
U.S. manufacturing scaling is underway in Hudson, NH, to support future commercialization.

The big picture

Alpha Tau Medical is positioning itself for a pivotal year in 2026, with multiple clinical milestones that could validate Alpha DaRT’s broad applicability in cancer treatment. The company’s strategy of parallel trials across diverse indications aims to accelerate regulatory approvals and commercialization, particularly in high-unmet-need areas like pancreatic and brain cancers. Success in these trials could significantly expand Alpha DaRT’s market potential beyond its current focus on localized tumors.

What we're watching

Regulatory Momentum: Whether Alpha Tau can secure its first commercial approval outside Israel through Japan’s pending decision.
Clinical Validation: The pace at which Alpha DaRT demonstrates efficacy across multiple cancer types, particularly in pancreatic and brain tumors.
Commercial Readiness: How Alpha Tau’s U.S. manufacturing scaling will impact its ability to meet future demand.